Chronic pruritus: modern data on epidemiology, pathogenesis, differential diagnosis and therapy
Patient-Oriented Medicine and Pharmacy · 21.07.2026 · 4 (2) · 46-64
DOI: 10.37489/2949-1924-0140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient-Oriented Medicine and Pharmacy, online erschienen am 21.07.2026. Verfasst von M. Yu. Savgacheva und 2 weiteren Autor:innen. Die Arbeit nennt 99 Literaturangaben.
Abstract (Originalsprache)
Background
Chronic pruritus (CP) is one of the most frequent complaints in the practice of a general physician, associated with a significant reduction in quality of life, sleep disturbance, anxiety and depression. The prevalence of CP in the general population reaches 13.5–22.0 %, and in persons over 65 years of age — up to 60 %, making the problem clinically and socially significant.
Objective
Based on the analysis of current guidelines and clinical studies, to summarize data on the epidemiology, pathogenesis, differential diagnosis and treatment of CP from a patient‑centered perspective. Data sources. An analysis of key sources was conducted: clinical guidelines, original studies and meta-analyses indexed in PubMed and the Cochrane Library, published on chronic itching. Key findings. Non‑histaminergic mechanisms dominate in the pathogenesis of CP: IL‑31, TSLP, μ/κ‑opioid receptor imbalance, activation of TRPV1/TRPA1 channels and JAK/STAT signaling. A three‑step diagnostic algorithm is proposed, including mandatory laboratory screening (complete blood count, ferritin, TSH, creatinine, liver function tests) and additional methods (ultrasound, skin biopsy, spinal MRI). Treatment includes correction of the underlying disease, the use of emollients, and stepwise prescription of systemic agents: naltrexone (for cholestasis), gabapentin (for neuropathic pruritus), antidepressants (paroxetine, mirtazapine), biologic therapy (dupilumab), and JAK inhibitors. Special attention is paid to shared decision‑making, consideration of patient preferences, and assessment of quality of life using the ItchyQOL and DLQI questionnaires.
Conclusion
The narrative review is intended for general physicians, dermatologists, neurologists, and general practitioners. Timely etiological diagnosis and stepwise pathogenetic therapy allow control of CP and prevention of psychosocial maladaptation of patients.
Zitieren
APA
Savgacheva, M. Y., Pleshcheva, T. N., & Ermoshina, M. E. (2026). Chronic pruritus: modern data on epidemiology, pathogenesis, differential diagnosis and therapy. Patient-Oriented Medicine and Pharmacy, 4(2), 46-64. https://doi.org/10.37489/2949-1924-0140
Vancouver
Savgacheva MY, Pleshcheva TN, Ermoshina ME. Chronic pruritus: modern data on epidemiology, pathogenesis, differential diagnosis and therapy. Patient-Oriented Medicine and Pharmacy. 2026;4(2):46-64. doi:10.37489/2949-1924-0140
BibTeX
@article{Savgacheva2026,
author = {Savgacheva, M. Yu. and Pleshcheva, T. N. and Ermoshina, M. E.},
title = {Chronic pruritus: modern data on epidemiology, pathogenesis, differential diagnosis and therapy},
journal = {Patient-Oriented Medicine and Pharmacy},
year = {2026},
volume = {4},
number = {2},
pages = {46--64},
doi = {10.37489/2949-1924-0140}
}
EUVIMED